Biology 2013, 2(3), 936-975; doi:10.3390/biology2030936
Review

Oncolytic Newcastle Disease Virus as Cutting Edge between Tumor and Host

1email and 1,2,* email
Received: 6 May 2013; in revised form: 11 June 2013 / Accepted: 18 June 2013 / Published: 2 July 2013
(This article belongs to the Special Issue RNA Viruses and Cancer)
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Abstract: Oncolytic viruses (OVs) replicate selectively in tumor cells and exert anti-tumor cytotoxic activity. Among them, Newcastle Disease Virus (NDV), a bird RNA virus of the paramyxovirus family, appears outstanding. Its anti-tumor effect is based on: (i) oncolytic activity and (ii) immunostimulation. Together these activities facilitate the induction of post-oncolytic adaptive immunity. We will present milestones during the last 60 years of clinical evaluation of this virus. Two main strategies of clinical application were followed using the virus (i) as a virotherapeutic agent, which is applied systemically or (ii) as an immunostimulatory agent combined with tumor cells for vaccination of cancer patients. More recently, a third strategy evolved. It combines the strategies (i) and (ii) and includes also dendritic cells (DCs). The first step involves systemic application of NDV to condition the patient. The second step involves intradermal application of a special DC vaccine pulsed with viral oncolysate. This strategy, called NDV/DC, combines anti-cancer activity (oncolytic virotherapy) and immune-stimulatory properties (oncolytic immunotherapy) with the high potential of DCs (DC therapy) to prime naive T cells. The aim of such treatment is to first prepare the cancer-bearing host for immunocompetence and then to instruct the patient’s immune system with information about tumor-associated antigens (TAAs) of its own tumor together with danger signals derived from virus infection. This multimodal concept should optimize the generation of strong polyclonal T cell reactivity targeted against the patient’s TAAs and lead to the establishment of a long-lasting memory T cell repertoire.
Keywords: RNA virus; tumor immunology; immunotherapy of solid tumors; tumor vaccination; virus; dendritic cells; danger signals; CD8 T-lymphocytes
PDF Full-text Download PDF Full-Text [1011 KB, uploaded 2 July 2013 10:32 CEST]

Export to BibTeX |
EndNote


MDPI and ACS Style

Fournier, P.; Schirrmacher, V. Oncolytic Newcastle Disease Virus as Cutting Edge between Tumor and Host. Biology 2013, 2, 936-975.

AMA Style

Fournier P, Schirrmacher V. Oncolytic Newcastle Disease Virus as Cutting Edge between Tumor and Host. Biology. 2013; 2(3):936-975.

Chicago/Turabian Style

Fournier, Philippe; Schirrmacher, Volker. 2013. "Oncolytic Newcastle Disease Virus as Cutting Edge between Tumor and Host." Biology 2, no. 3: 936-975.

Biology EISSN 2079-7737 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert